NAS10029,447+1.73%S&P7,638+1.14%GOLD$4,384−0.08%BTC$76,220+0.09%VIX15.44−12.82%live tape · as of 23:00 UTC · 17 Sep
The Screen · Healthcare · Medical Care Facilities
Guardian Pharmacy Services, Inc.
GRDN · the NYSE · USD · Market cap $3.0B · 3,600 employees
Guardian Pharmacy Services, Inc., a pharmacy service company, provides a suite of technology-enabled services to help residents of long-term health care facilities (LTCFs) in the United States.
Screened 2026-09-15 · the tape above runs as of 23:00 UTC · 17 Sep · two dates, stated on purpose · verdict and workings shown in full · never trimmed
The Label · The Season, Not the Day
This name holds its accumulation label.
Guardian Pharmacy Services, Inc. holds its Accumulation at $48.00. The statistical read favours the buyers, held for 1 days.
As held on the ledger · 2026-09-15
Phase
Accumulation
Quantitative state
The statistical read favours the buyers, held for 1 days
Price at the screen
$48.00
Valuation
46.15 trailing · 33.57 forward price to earnings
Values screen
PASS· score 70.0
The Workings
Five Screens, Shown in Full
Full pass across all five screens. This security clears the Titan Ethical Standard: its business and its balance sheet both stay inside the lines.
Test
Figure
Limit
What it means
Status
Business activity
Permissible
Core business clean
Its core business isn't built on prohibited lines: no gambling, alcohol, tobacco, weapons, or interest-based lending.
Pass
Debt load
9.00%
Below 33%
Interest-bearing debt is just 9.0% of its assets, well under the one-third ceiling: it does not run on borrowed money.
Pass
Interest-bearing cash
0.00%
Below 33%
Cash held in interest-bearing accounts and securities is 0.0% of assets, under the one-third limit.
Pass
Receivables
40.53%
Below 49%
Money owed to the company is 40.5% of assets, under the 49% limit.
Pass
Revenue purity
0.00%
Below 5%
Only 0.0% of revenue comes from non-compliant sources, under the 5% line.
Pass
Five checks adapted from AAOIFI screening standards: business activity plus four balance-sheet ratios. All five must pass for ethical clearance. Every figure is arithmetic on public accounts, not judgement.
Fair value range in USD, drawn from the 2026-09-15 screen. The gold marker is the market price at the same screen. The price runs 15.7% above the base estimate.
Third-party analyst targets: 6 covering, consensus Strong Buy. The average target sits +3% from the screen price.
Reading the gap · Both our model and the Street see limited upside at this price.
Price History & Projections
Where it has been, where the models see it going. History from market close data; projection points are our fair-value estimates and third-party analyst targets, dated to the 2026-09-15 screen.
Fair value and rating are our own model estimates; the Street's range reflects third-party analyst estimates. Analysis, not advice.
The Business, in Plain Words
Care home pharmacies trade above fair value
Every pill dispensed inside a US nursing home moves through specialised pharmacy networks that keep residents medicated on time. Guardian Pharmacy Services runs that operation, supplying tech-enabled dispensing and clinical support to long-term care facilities across the country.
Revenue is expanding at just 2% while the forward multiple sits at 29.8 times and margins remain stuck at 4%. The shares trade at 40.52 against a fair value of 38.44, so there is no margin of safety and the opportunity rating stays at none despite the clean ethical screen.
Return on equity reaches 27%, yet unknown competitive strength and thin growth leave the business exposed to reimbursement cuts and regulatory shifts in healthcare. Analysts see a median target of 47, but that does not change the lack of value on offer today.
The risks · The main risks here are ordinary market swings and the chance our fair-value read proves too optimistic.
Plain-English interpretation of our own screen data. Analysis, not advice.
Where & How to Trade
GRDN trades on the NYSE. As a listed security it is accessible through almost any international broker offering its home market. New to this, or investing from abroad? Our guide to accessing global markets covers brokers, currencies and the practical steps.
The framework has shifted from accumulation to distribution since the last review. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved down 7.5% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it A, carrying a low risk profile. Technically it is holding around 24% above its long-term trend line with momentum reading bullish. Over the past year the shares are up 103%. Our forward projection puts the odds of a 10% gain over the next month near 40%. The street (6 analysts) rates it strong buy, with a mean price target of $43.
2026-07-31Accumulation$40.52-6.0%Entry 4
The framework reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 6.0% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it A, carrying a low risk profile. Technically it is holding around 24% above its long-term trend line with momentum reading bullish. Over the past year the shares are up 103%. Our forward projection puts the odds of a 10% gain over the next month near 40%. The street (6 analysts) rates it strong buy, with a mean price target of $43.
2026-07-18Accumulation$43.09+0.0%Entry 3
The framework reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 0.0% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it A, carrying a low risk profile. Technically it is holding around 24% above its long-term trend line with momentum reading bullish. Over the past year the shares are up 103%. Our forward projection puts the odds of a 10% gain over the next month near 40%. The street (6 analysts) rates it strong buy, with a mean price target of $43.
2026-07-03Accumulation$43.09+0.0%Entry 2
The framework reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 0.0% since our last review. Ethical screening: PASS with passing ethical screen (70). The risk-adjusted return profile shows excellent risk-adjusted returns.
2026-07-02Accumulation$43.09Entry 1
The framework reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Ethical screening: PASS with passing ethical screen (70). The risk-adjusted return profile shows excellent risk-adjusted returns.
Each entry above was written on its date, before the outcome. A journal you can prune is not a journal.